Cempra Reports First Quarter 2017 Financial Results and Provides Corporate Update
CHAPEL HILL, N.C., April 28, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the quarter ended March 31, 2017 and provided an update on recent corporate developments. The company will host a webcast and conference call today at 8:45 a.m. ET.
“With our sizable cash resources and the significant cost reduction actions we took in the first quarter, along with advancing the regulatory process for solithromycin and fusidic acid and the robust process we have underway to evaluate potential strategic business opportunities, we believe we are well-positioned to deliver value to patients and shareholders,” said David Zaccardelli, Pharm.D., acting chief executive officer of Cempra.
“With our sizable cash resources and the significant cost reduction actions we took in the first quarter, along with advancing the regulatory process for solithromycin and fusidic acid and the robust process we have underway to evaluate potential strategic business opportunities, we believe we are well-positioned to deliver value to patients and shareholders,” said David Zaccardelli, Pharm.D., acting chief executive officer of Cempra.